Amrita Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amrita Singh has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Kumar
School of Pharmaceutical Sciences, Chhatrapati Shahu Ji Maharaj University
2 shared publications - Ankit Kumar
School of Pharmaceutical Sciences, Chhatrapati Shahu Ji Maharaj University
2 shared publications - Mohd. Obaid
School of Pharmaceutical Sciences, Chhatrapati Shahu Ji Maharaj University
2 shared publications - Ashish Tiwari
School of Pharmaceutical Sciences, Chhatrapati Shahu Ji Maharaj University, Kanpur, 208024, India
1 shared publication - Ayush Katiyar
Chhatrapati Shahu Ji Maharaj University School of Pharmaceutical Sciences Kanpur India
1 shared publication - Himanshi Bhadauria
School of Pharmaceutical Sciences, CSJM University
1 shared publication
Latest Publications
- 17 September 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26, 1-40
The 1,3,4-Thiadiazole Scaffold in Medicinal Chemistry: Structural Insights, Mechanistic Pathways, and Therapeutic Outlook
Heteroatoms are common structural fragments in many APIs and excipients. Several heterocyclic scaffolds are considered privileged structures. The term Thiadiazole comes from the “Hantzsch-Widman” nomenclature and falls within the category of azole chemicals. These are heterocyclic compounds with 5-membered rings that contain 2 nitrogen atoms and 1 sulfur atom. It exists in 4 isomeric forms, namely 1,2,4-thiadiazole, 1,2,3-thiadiazole, 1,3,4-thiadiazole, and 1,2,5- thiadiazole. The thiadiazole nucleus shows a broad spectrum of biological activities, including antimicrobial, anticonvulsant, anticancer, antiviral, antituberculosis, anti-inflammatory and analgesic, diuretic, antidiabetic, anti-ulcer, antimalarial, and anti-leishmanicidal properties, as well as effects against influenza, hypolipidemia, hyperlipidemia, and hypertension. The most studied of these scaffolds is the 1,3,4-thiadiazole scaffold, and the synthesis of 1,3,4-thiadiazole proceeds through wellestablished reaction pathways, including the intramolecular cyclization of thioacylated intermediates, including acylhydrazide or thiosemicarbazide derivatives, which are either acid- or basecatalyzed and often facilitated by harsh dehydrating agents. The review also addresses the chemical reactivity, substitution behaviour, and stability of the scaffold under various conditions, thereby making it more adaptable for molecular design. Aromatic stability, unique electron distribution, and bioisosteric physicochemical and electronic characteristics of the 1,3,4-thiadiazole core result in improved pharmacodynamic and pharmacokinetic performance, and the use of the 1,3,4-thiadiazole ring is currently and, in the future, a major structural motif in drug discovery. This review summarizes emerging information on the chemistry of 1,3,4-thiadiazole and promotes the exploration of this versatile scaffold for developing new therapeutic agents.
- 17 September 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26, 1-40
The 1,3,4-Thiadiazole Scaffold in Medicinal Chemistry: Structural Insights, Mechanistic Pathways, and Therapeutic Outlook
Heteroatoms are common structural fragments in many APIs and excipients. Several heterocyclic scaffolds are considered privileged structures. The term Thiadiazole comes from the “Hantzsch-Widman” nomenclature and falls within the category of azole chemicals. These are heterocyclic compounds with 5-membered rings that contain 2 nitrogen atoms and 1 sulfur atom. It exists in 4 isomeric forms, namely 1,2,4-thiadiazole, 1,2,3-thiadiazole, 1,3,4-thiadiazole, and 1,2,5- thiadiazole. The thiadiazole nucleus shows a broad spectrum of biological activities, including antimicrobial, anticonvulsant, anticancer, antiviral, antituberculosis, anti-inflammatory and analgesic, diuretic, antidiabetic, anti-ulcer, antimalarial, and anti-leishmanicidal properties, as well as effects against influenza, hypolipidemia, hyperlipidemia, and hypertension. The most studied of these scaffolds is the 1,3,4-thiadiazole scaffold, and the synthesis of 1,3,4-thiadiazole proceeds through wellestablished reaction pathways, including the intramolecular cyclization of thioacylated intermediates, including acylhydrazide or thiosemicarbazide derivatives, which are either acid- or basecatalyzed and often facilitated by harsh dehydrating agents. The review also addresses the chemical reactivity, substitution behaviour, and stability of the scaffold under various conditions, thereby making it more adaptable for molecular design. Aromatic stability, unique electron distribution, and bioisosteric physicochemical and electronic characteristics of the 1,3,4-thiadiazole core result in improved pharmacodynamic and pharmacokinetic performance, and the use of the 1,3,4-thiadiazole ring is currently and, in the future, a major structural motif in drug discovery. This review summarizes emerging information on the chemistry of 1,3,4-thiadiazole and promotes the exploration of this versatile scaffold for developing new therapeutic agents.
- Open Access
- 29 October 2025
- Published by IJPHI GlobalPublisher Pvt. Ltd. in International Journal of Pharmaceutical and Healthcare Innovation
- Vol. 3 (I) , 788-821
Holistic and Conventional Approaches in Alzheimer’s Therapy: Exploring Herbal, Synthetic, and Alternative Interventions
Alzheimer’s disease (AD) is a progressive and irreversible neurological condition characterized by a steady and progressive impairment of different domains or sectors of cognition, such as language, learning and memory, attention, and social skills. Kraepelin used the term Alzheimer’s disease to describe the condition before it was first described by a German psychiatrist known as Alois Alzheimer in 1906. A study conducted in 2023 shows that 6.7 million of the American citizens aged 65 and over have Alzheimer’s disease. It is also possible that by 2060, 13.8 million sufferers of Alzheimer’s sufferers will exist unless significant progress is achieved in the field of science to prevent, treat, or cure the disease. Tau and amyloid-β (Aβ) are the defining molecules of Alzheimer’s disease and form neurofibrillary tangles and senile plaques. The main clinical aim of Alzheimer disease is to reduce its development, because there is currently no treatment. Synthetic preparations, which only attenuate symptoms, include cholinesterase inhibitors and NMDA receptor inhibitors (donepezil, rivastigmine, galantamine, and memantine). Unlike synthetic drugs, herbal medicines are more flexible over time and produce fewer side effects, such as inability to sleep, developing withdrawal symptoms, and adversely affecting other vital organs that are common with synthetic drugs. The first objective of this paper was to establish a review of how AD is being treated by searching databases such as PubMed, Web of Science, ResearchGate, Mdpi, Google Scholar, Science Direct, Willey, and many other websites.
- 29 October 2025
- Published by IJPHI GlobalPublisher Pvt. Ltd. in International Journal of Pharmaceutical and Healthcare Innovation
- Vol. 3 (I) , 788-821
Open AccessHolistic and Conventional Approaches in Alzheimer’s Therapy: Exploring Herbal, Synthetic, and Alternative Interventions
Alzheimer’s disease (AD) is a progressive and irreversible neurological condition characterized by a steady and progressive impairment of different domains or sectors of cognition, such as language, learning and memory, attention, and social skills. Kraepelin used the term Alzheimer’s disease to describe the condition before it was first described by a German psychiatrist known as Alois Alzheimer in 1906. A study conducted in 2023 shows that 6.7 million of the American citizens aged 65 and over have Alzheimer’s disease. It is also possible that by 2060, 13.8 million sufferers of Alzheimer’s sufferers will exist unless significant progress is achieved in the field of science to prevent, treat, or cure the disease. Tau and amyloid-β (Aβ) are the defining molecules of Alzheimer’s disease and form neurofibrillary tangles and senile plaques. The main clinical aim of Alzheimer disease is to reduce its development, because there is currently no treatment. Synthetic preparations, which only attenuate symptoms, include cholinesterase inhibitors and NMDA receptor inhibitors (donepezil, rivastigmine, galantamine, and memantine). Unlike synthetic drugs, herbal medicines are more flexible over time and produce fewer side effects, such as inability to sleep, developing withdrawal symptoms, and adversely affecting other vital organs that are common with synthetic drugs. The first objective of this paper was to establish a review of how AD is being treated by searching databases such as PubMed, Web of Science, ResearchGate, Mdpi, Google Scholar, Science Direct, Willey, and many other websites.
- 28 July 2025
- Published by Taylor & Francis in Molecular Crystals and Liquid Crystals
- Vol. 769 (11-12) , 1110-1138
“1,3-thiazoles: Advances in synthesis, properties, and biological potential”
- 28 July 2025
- Published by Taylor & Francis in Molecular Crystals and Liquid Crystals
- Vol. 769 (11-12) , 1110-1138
“1,3-thiazoles: Advances in synthesis, properties, and biological potential”